Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Daniela Betea in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Department of Pathological Cytology and Anatomy, Foch Hospital, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean-Claude Reubi in
Google Scholar
PubMed
Search for other papers by Catherine Waeber Stephan in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
; in particular those with AIP mutations have a significantly lower hormonal response to first-generation, receptor subtype 2 (SST2) specific somatostatin analogs (octreotide and lanreotide) and have a decreased rate of tumor shrinkage on treatment
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Search for other papers by Feng Gu in
Google Scholar
PubMed
Search for other papers by Marcello D Bronstein in
Google Scholar
PubMed
Search for other papers by Thierry C Brue in
Google Scholar
PubMed
Search for other papers by Maria Fleseriu in
Google Scholar
PubMed
Search for other papers by Ilan Shimon in
Google Scholar
PubMed
Search for other papers by Aart J van der Lely in
Google Scholar
PubMed
Search for other papers by Shoba Ravichandran in
Google Scholar
PubMed
Search for other papers by Albert Kandra in
Google Scholar
PubMed
Search for other papers by Alberto M Pedroncelli in
Google Scholar
PubMed
Search for other papers by Annamaria A L Colao in
Google Scholar
PubMed
with these agents ( 9 ). Long-acting pasireotide, a multireceptor-targeted somatostatin analog (SSA), has been evaluated in the Phase III SOM230C2305 (C2305) ( 10 ) and SOM230C2402 (C2402; PAOLA) ( 11 ) studies. Patients enrolled in study C2305 had
Search for other papers by Alberto Bongiovanni in
Google Scholar
PubMed
Search for other papers by Federica Recine in
Google Scholar
PubMed
Search for other papers by Flavia Foca in
Google Scholar
PubMed
Search for other papers by Valentina Fausti in
Google Scholar
PubMed
Search for other papers by Nada Riva in
Google Scholar
PubMed
Search for other papers by Greta Fabbri in
Google Scholar
PubMed
Search for other papers by Stefano Severi in
Google Scholar
PubMed
Search for other papers by Chiara Liverani in
Google Scholar
PubMed
Search for other papers by Alessandro De Vita in
Google Scholar
PubMed
Search for other papers by Chiara Spadazzi in
Google Scholar
PubMed
Search for other papers by Giacomo Miserocchi in
Google Scholar
PubMed
Search for other papers by Laura Mercatali in
Google Scholar
PubMed
Search for other papers by Dino Amadori in
Google Scholar
PubMed
Search for other papers by Toni Ibrahim in
Google Scholar
PubMed
reported in <15% of cases ( 7 ). Treatment options for metastatic disease comprise liver surgery and/or locoregional and ablative therapies, somatostatin analogs, chemotherapy, targeted therapy and peptide receptor radionuclide therapy ( 8 ). Given the
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by David A Cano in
Google Scholar
PubMed
Search for other papers by Eva Venegas-Moreno in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Elena Dios in
Google Scholar
PubMed
Search for other papers by Emilie Castermans in
Google Scholar
PubMed
Search for other papers by Alvaro Flores-Martínez in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by Alfonso Soto-Moreno in
Google Scholar
PubMed
patients may be resistant to somatostatin analogs (SSA) that target the somatostatin receptor subtype 2 (SST2), while a small proportion of prolactinoma patients may not respond to labeled doses of dopamine agonists (DA). Hence, multimodal therapy involving
Search for other papers by Paweł Komarnicki in
Google Scholar
PubMed
Search for other papers by Paweł Gut in
Google Scholar
PubMed
Search for other papers by Jan Musiałkiewicz in
Google Scholar
PubMed
Search for other papers by Maja Cieślewicz in
Google Scholar
PubMed
Search for other papers by Adam Maciejewski in
Google Scholar
PubMed
Search for other papers by Prachi Patel in
Google Scholar
PubMed
Search for other papers by George Mastorakos in
Google Scholar
PubMed
Search for other papers by Marek Ruchała in
Google Scholar
PubMed
in NETs. Patients and methods Patients, inclusion and exclusion criteria We have retrospectively analyzed an institutional database of patients diagnosed with midgut NET and treated with long-acting somatostatin analogs (octreotide
Search for other papers by Caiyan Mo in
Google Scholar
PubMed
Search for other papers by Tao Tong in
Google Scholar
PubMed
Search for other papers by Ying Guo in
Google Scholar
PubMed
Search for other papers by Zheng Li in
Google Scholar
PubMed
Search for other papers by Liyong Zhong in
Google Scholar
PubMed
factor 1; M, man; SSA, somatostatin analog; TRAb, thyroid-stimulating hormone receptor antibodies; TSH, thyroid-stimulating hormone; TSS, transsphenoidal surgery; TT3, total triiodothyronine; TT4, total thyroxine;. Among the included patients
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
Search for other papers by Harry Aslanian in
Google Scholar
PubMed
Wren Laboratories, Yale University School of Medicine, 35 NE Industrial Road, Branford, Connecticut, USA
Search for other papers by Lisa Bodei in
Google Scholar
PubMed
Search for other papers by Ignat Drozdov in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
. Disease was localized in 28% and was distant in 67%. No pathology and staging was available in 12 (10%) patients. Twenty-two percent were treatment naïve, while 26% were currently being treated with somatostatin analogs, and 9% (11 patients, all Zollinger
Search for other papers by Sara Storvall in
Google Scholar
PubMed
Search for other papers by Helena Leijon in
Google Scholar
PubMed
Search for other papers by Eeva Ryhänen in
Google Scholar
PubMed
Search for other papers by Johanna Louhimo in
Google Scholar
PubMed
Search for other papers by Caj Haglund in
Google Scholar
PubMed
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Search for other papers by Johanna Arola in
Google Scholar
PubMed
in leukocytes, endothelial cells and macrophages ( 19 ). Somatostatin analogs are widely used in the treatment of different neuroendocrine tumors, such as ACTH-producing pituitary adenomas, somatotropinomas and gastropancreatic neuroendocrine
Search for other papers by Bernardo Maia in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
A Maamari R et al . Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs . Frontiers in Endocrinology 2019 10 931. ( https
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Search for other papers by G Giuffrida in
Google Scholar
PubMed
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by F Ferraù in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by R Laudicella in
Google Scholar
PubMed
Search for other papers by O R Cotta in
Google Scholar
PubMed
Search for other papers by E Messina in
Google Scholar
PubMed
Neuroradiology Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F Granata in
Google Scholar
PubMed
Neurosurgery Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F F Angileri in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by A Vento in
Google Scholar
PubMed
Search for other papers by A Alibrandi in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by S Baldari in
Google Scholar
PubMed
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by S Cannavò in
Google Scholar
PubMed
) and second generation (pasireotide) somatostatin analogs (SSa), and the rationale of the use of radiolabeled-SSa for diagnostic imaging and PRRT ( 111 In-pentreotide, 177 Lu-DOTA, 90 Y-DOTA, 68 Ga-DOTA) ( 8 , 9 ). Herein we report on the